TD Cowen lowered the firm’s price target on Moderna (MRNA) to $35 from $55 and keeps a Hold rating on the shares. The firm updated its model and decreased its Q4 revenue estimates for Spikevax and mRESVIA and decreased OpEx estimates to reflect the pre-announcement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna downgraded to Neutral from Buy at Goldman Sachs
- Moderna price target lowered to $50 from $60 at Evercore ISI
- Moderna awarded tender for COVID-19 vaccine in EU, Norway and North Macedonia
- Moderna Secures EU Tender for mRNA COVID-19 Vaccine Supply
- Why I Don’t Believe Larry Ellison’s Moderna Stock Hype